Emicizumab Activity
Also known as: Hemlibra
Use
This assay is intended for the evaluation of plasma emicizumab levels (µg/mL) in patients receiving emicizumab therapy.
Special Instructions
Not provided.
Limitations
Patients receiving factor VIII replacement therapy in addition to emicizumab may show falsely elevated results, as will patients with significant native factor VIII levels (greater than 25% native factor VIII activity). For assessment of factor VIII inhibitor levels while the patient is on emicizumab, an alternate test (Factor VIII Chromogenic Bethesda Profile, for Patients on Emicizumab [504722]) is recommended. This test was developed and its performance characteristics determined by Labcorp; it has not been cleared or approved by the Food and Drug Administration.
Methodology
Other
Biomarkers
LOINC Codes
- 99614-0
- 99614-0
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
0.5 mL
Container
Light blue-top (3.2% sodium citrate) collection tube
Collection Instructions
Separate plasma from cells by centrifugation. Centrifuge separated plasma to yield platelet-poor plasma. Transfer plasma to a plastic transport tube before freezing.
Storage Instructions
Freeze. Stable at room temperature for 6 hours, and for 3 additional freeze/thaw Instructions cycles.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 6 hours |